Market revenue in 2024 | USD 146.7 million |
Market revenue in 2030 | USD 320.7 million |
Growth rate | 13.9% (CAGR from 2025 to 2030) |
Largest segment | Exocrine |
Fastest growing segment | Endocrine |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Exocrine, Endocrine |
Key market players worldwide | Accuray Inc, AstraZeneca PLC ADR, Novartis AG ADR, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Ipsen Pharma, Eli Lilly and Co, Siemens Healthineers AG ADR, Elekta AB ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer treatment market will help companies and investors design strategic landscapes.
Exocrine was the largest segment with a revenue share of 88.41% in 2024. Horizon Databook has segmented the China pancreatic cancer treatment market based on exocrine, endocrine covering the revenue growth of each sub-segment from 2018 to 2030.
The pancreatic cancer treatment market in China presents a highly competitive environment, driven by the increasing prevalence of the disease and rapid advancements in healthcare infrastructure. According to WHO, China recorded 118,672 new cases of pancreatic cancer in 2022.
Companies are intensifying their focus on the Chinese market. AstraZeneca has reported a 22% growth in patient enrollment in its clinical trials for targeted therapies in China over the past three years, leveraging the country’s expanding clinical research capabilities.
Similarly, Novartis AG has launched partnerships with Chinese research institutions to expedite the development and approval of innovative treatments tailored to the genetic profiles of local patients.
Horizon Databook provides a detailed overview of country-level data and insights on the China pancreatic cancer treatment market , including forecasts for subscribers. This country databook contains high-level insights into China pancreatic cancer treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account